Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells

Click to increase image sizeClick to decrease image size

Acknowledgments

M.B.G. is supported in part by a grant from the NIH/National Center for Advancing Translational Sciences [UL1TR00457], administered by the Clinical and Translational Science Center at Weill Cornell Medical Center and MSKCC, and by the Lymphoma Research Foundation. A.G.E. is supported by the Wilmot Cancer Research Fellowship at the University of Rochester and Wilmot Cancer Institute. J.H.P. is supported by grants from the American Society of Clinical Oncology Career Development Award and the National Comprehensive Cancer Network Young Investigator Award. M.L.D. is supported by a Damon Runyon Clinical Investigator Award and American Society of Hematology/Amos Medical Faculty Development Program Award. I.R. is supported by a grant from the NIH/National Cancer Institute [P30-CA08748]. R.J.B. is supported by The Damon Runyon Clinical Investigator Award, The Translational and Integrative Medicine Fund Research Grant (MSKCC), The Annual Terry Fox Run for Cancer Research (New York, NY) organized by the Canada Club of New York, Carson Family Charitable Trust, Kate’s Team, Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research, the Experimental Therapeutics Center of MSKCC, The Geoffrey Beene Cancer Foundation, and The Bocina Cancer Research Fund.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1390237.